Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of nefopam on opioid consumption in full-house endoscopic sinus surgery
TCTR20241231003Phase 4Recruiting
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nefopam in chronic rhinosinusitis (CRS) (2 arms), sponsored by Ratchadaphiseksomphot Endowment Fund. Primary endpoint: Opioid consumption during and after surgery. Started Jan 2025; status: recruiting.
02
Drugs
nefopam
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on TCTR20241231003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20241231003.